Clinical trials registries were searched to identify any ongoing studies among women with menopausal symptoms who were treated for breast cancer. The following trials were identified (full details can be found in Section 3.9 of the systematic review):
- NCT01908270: A single blind RCT (Germany) in women treated for breast cancer with a score of ≥ 5 on the Menopausal Rating Scale (MRS) comparing yoga with usual care. The study has been completed but no published results were available at the time the systematic review was undertaken. N=40.
- NCT02091765: A RCT (the Netherlands) in women treated for breast cancer with menopausal symptoms comparing an internet-based cognitive behavioural therapy intervention with a minimal intervention control group. N=160.
- NCT01275807: An open-label RCT (Italy) in women with breast cancer receiving endocrine therapy and experiencing menopausal symptoms comparing acupuncture with self-case. N=210.
- NCT01900418: A single-blind RCT (US) in women with breast cancer receiving endocrine therapy with mild joint pain/symptoms comparing walking with no intervention. N=80.
- NCT00156416: A single-blind, pilot study RCT (US) in women with breast cancer and amenorrhoea secondary to breast cancer treatment, as well as menopausal symptoms comparing mindfulness medication with attention. N=60.
- NCT01246427: A double-blind RCT (France) in women receiving at least 1 month of adjuvant therapy for breast cancer who are experiencing menopausal symptoms comparing the homeopathic drug BRN01 with placebo. N=138.
- NCT02672189: A RCT (the Netherlands) of Internet-based CBT for breast cancer patients with climacteric symptoms. N=265.
- NCT01573442: A double-blind RCT (US) of subcutaneous testosterone in the adjuvant treatment of postmenopausal women with aromatase inhibitor induced arthralgias. N=224.
- ACTRN12615000083594: A double-blind RCT (Australia) investigating the efficacy and safety of intra-vaginal testosterone for the treatment of vulvo-vaginal atrophy associated with aromatase inhibitor therapy in women with breast cancer. N=100
After the literature searches were concluded, an additional Australian trial on the use of water-based and silicon based lubricants in women after breast cancer was published.100 The randomised crossover trial found no significant difference in total sexual discomfort between water-based and silicon based lubricants. However; a post hoc analysis showed that, pain/discomfort during penetration improved more with silicone-based lubricant use than with water-based lubricant.